| Literature DB >> 22577404 |
Michael D Freeman1, Sean S Kohles.
Abstract
Polychlorinated biphenyls (PCBs) are synthetic chlorinated hydrocarbons that have extensively polluted the environment and bioaccumulated in the food chain. PCBs have been deemed to be probable carcinogens by the Environmental Protection Agency, and exposure to high levels of PCBs has been consistently linked to increased risk of non-Hodgkin lymphoma (NHL). In the present article we present a forensic epidemiologic evaluation of the causal relationship between NHL and elevated PCB levels via application of the Bradford-Hill criteria. Included in the evaluation is a meta-analysis of the results of previously published case-control studies in order to assess the strength of association between NHL and PCBs, resulting in an odds ratio in which the lowest percentile PCB concentration (quartile, quintile, or tertile) has been compared with the highest percentile concentration in the study groups. The weight-adjusted odds ratio for all PCB congeners was 1.43 with a 95% confidence interval of 1.31 to 1.55, indicating a statistically significant causal association with NHL. Because of the lack of an unexposed comparison group, a rationale for the use of a less than 2.0 relative risk causal contribution threshold is presented herein, including an ecologic analysis of NHL incidence and PCB accumulation (as measured by sales volume) over time. The overall results presented here indicate a strong general causal association between NHL and PCB exposure.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22577404 PMCID: PMC3346688 DOI: 10.1155/2012/258981
Source DB: PubMed Journal: J Environ Public Health ISSN: 1687-9805
Summary of published case-control study populations examining risk of NHL and PCB blood content including those meta-analyzed in the present study. Summed or total PCB metrics shown here.
| Study (notes, conc values) | Percentile | PCB conc (ng/g lipid) | Min conc | Max conc | Case sample size | Control sample size | OR | 95% LCL | 95% UCL | Meta-analysis inclusion |
|---|---|---|---|---|---|---|---|---|---|---|
|
Rothman et al. 1997 (mean conc) [ | Total | 74 | 147 | |||||||
| 1 | 526 | 247 | 641 | 10 | 37 | 1.00 | ||||
| 2 | 727 | 649 | 806 | 13 | 37 | 1.30 | 0.5 | 3.3 | No | |
| 3 | 924 | 814 | 1060 | 21 | 37 | 2.80 | 1.1 | 7.6 | ||
| 4 | 1430 | 1070 | 2070 | 30 | 36 | 4.50 | 1.7 | 12.0 | ||
|
| ||||||||||
|
Engel et al., 2007 (Janus cohort, median conc) [ | Total | 190 | 190 | |||||||
| 1 | 1048.3 | 44 | 48 | 1.00 | ||||||
| 2 | 1398.3 | 48 | 47 | 1.10 | 0.7 | 2.0 | Yes | |||
| 3 | 1674.9 | 38 | 48 | 1.00 | 0.5 | 1.9 | ||||
| 4 | 2148.2 | 60 | 47 | 1.70 | 0.8 | 3.4 | ||||
|
| ||||||||||
|
Engel et al., 2007 (CLUE 1 cohort median conc) [ | Total | 74 | 147 | |||||||
| 1 | 551.4 | 10 | 37 | 1.00 | ||||||
| 2 | 726 | 13 | 37 | 1.10 | 0.7 | 2.0 | Yes | |||
| 3 | 911.5 | 21 | 37 | 1.00 | 0.5 | 1.9 | ||||
| 4 | 1377.3 | 30 | 36 | 1.70 | 0.8 | 3.4 | ||||
|
| ||||||||||
|
Spinelli et al., 2007 (Median conc) [ | Total | 403 | ||||||||
| 1 | <100.9 | 100.9 | 81 | 115 | 1.00 | |||||
| 2 | >100.9 | 155.6 | 103 | 114 | 1.41 | 0.93 | 2.14 | Yes | ||
| 3 | >155.6 | 220 | 77 | 115 | 1.11 | 0.71 | 1.74 | |||
| 4 | >220 | 6571 | 142 | 115 | 2.14 | 1.38 | 3.30 | |||
|
| ||||||||||
|
De Roos et al., 2005 [ | Total | 97 | 96 | |||||||
| 1 | <6.4 | 6.4 | 28 | 24 | 1.00 | |||||
| 2 | >6.4 | 8.69 | 16 | 25 | 0.59 | 0.25 | 1.40 | Yes | ||
| 3 | >8.69 | 13.17 | 20 | 23 | 0.86 | 0.38 | 1.98 | |||
| 4 | >13.17 | 33 | 24 | 1.51 | 0.62 | 3.67 | ||||
|
| ||||||||||
| Laden et al., 2010 (median conc) [ | Total | 145 | 290 | |||||||
| 1 | 406.9 | 33 | 72 | 1.00 | ||||||
| 2 | 547.8 | 41 | 73 | 1.22 | 0.69 | 2.18 | Yes | |||
| 3 | 678.0 | 41 | 73 | 1.22 | 0.69 | 2.18 | ||||
| 4 | 945.4 | 30 | 72 | 0.91 | 0.50 | 1.67 | ||||
|
| ||||||||||
|
Hardell et al., 2001 (36 PCBs, mean conc) [ | Total | 1436 | 331 | 4706 | 82 | 83 | 1.00 | |||
| 1 | 1296 (med) | 4706 | 51 | 41 | 1.80 | 0.85 | 3.9 | No | ||
|
| ||||||||||
|
Hardell et al., 2001 (11 immunotoxic PCBs) [ | Total | 511 | 118 | 1598 | 82 | 83 | 1.00 | |||
| 1 | 462 (med) | 1598 | 57 | 40 | 3.20 | 1.4 | 7.4 | No | ||
|
| ||||||||||
|
Hardell et al., 2006; [ | Total | 860 | 102 | 4222 | 97 | 98 | 1.00 | |||
| 1 | 762 (med) | 4222 | 59 | 49 | 2.00 | 0.99 | 3.99 | No | ||
|
| ||||||||||
|
Hardell et al., 2006; [ | Total | 290 | 41 | 1297 | 97 | 98 | 1.00 | |||
| 1 | 238 (med) | 1297 | 54 | 49 | 1.50 | 0.8 | 3.0 | No | ||
|
| ||||||||||
|
Cocco et al., 2008 [ | Total | 174 | ||||||||
| 1 | <200.42 | 200.42 | 41 | 51 | 1.00 | |||||
| 2 | 200.43 | 387.79 | 50 | 51 | 1.20 | 0.6 | 2.2 | Yes | ||
| 3 | 387.8 | 576.36 | 33 | 50 | 0.70 | 0.3 | 1.4 | |||
| 4 | 576.37 | >576.37 | 50 | 51 | 1.00 | 0.5 | 2.0 | |||
|
| ||||||||||
|
Quintana et al., 2004 [ | Total | |||||||||
| 1 | <1000 | 1000 | 79 | 184 | 1.00 | |||||
| 2 | >1000 | 3000 | 50 | 151 | 1.05 | 0.63 | 1.76 | No | ||
| 3 | >3000 | 9 | 23 | 1.08 | 0.40 | 2.92 | ||||
|
| ||||||||||
| Bertrand et al., 2010 (median conc) [ | Total | 205 | 409 | |||||||
| 1 | 518 | 163 | 617 | 33 | 81 | 1..00 | ||||
| 2 | 678 | >617 | 742 | 31 | 82 | 0.92 | 0.51 | 1.60 | Yes | |
| 3 | 815 | >742 | 894 | 34 | 82 | 1.00 | 0.60 | 1.80 | ||
| 4 | 980 | >894 | 1121 | 46 | 82 | 1.40 | 0.71 | 2.20 | ||
| 5 | 1385 | >1121 | 5322 | 61 | 82 | 1.90 | 0.94 | 2.90 | ||
Summary of published cohort studies examining mortality from NHL as associated with PCB exposure. Note the cohort described in Prince et al., [50] were included in the Prince et al., [51] study. Here, the standardized mortality ratio (SMR) was calculated as an indirect adjustment method where the observed number of events (deaths) in each occupational cohort is compared with the number of expected events (based on a “standard” rate).
| Study | PCB product exposure | Chlorine (%) | PCB air sampling ( | Cohort size ( | Deaths | Cancer deaths | NHL deaths | Mortality rate (SMR) |
|---|---|---|---|---|---|---|---|---|
|
Prince et al., 2006 [ | Aroclor 1254 | 54 | 24–476 & 50–1,260 | 2,572 | 798 | 218 | 10 | 1.31 |
| Aroclor 1242 | 42 | |||||||
| Aroclor 1016 | 41 | |||||||
|
| ||||||||
|
Prince et al., 2006 [ | Aroclor 1254 | 54 | 24–476 & 50–1,260 | 14,458 | 3,417 | 1015 | 35 | 0.98 |
| Aroclor 1242 | 42 | |||||||
| Aroclor 1016 | 41 | |||||||
|
| ||||||||
|
Ruder et al., 2006 [ | Aroclor 1242 | 42 | 7–339 & 62–290 | 3,569 | 547 | 171 | 9 | 1.23 |
| Aroclor 1016 | 41 | |||||||
Notation for the calculation of Mantel-Haenszel-adjusted odds ratios from the published case-control studies reporting association of NHL and PCB blood content for specific congeners. Here, “exposed” and “unexposed” populations noted in traditional meta-analyses were replaced with “upper” and “lower” acknowledging the upper and lower percentiles of exposure reported in the literature, respectively. The subscript “i” indicates each stratum (published congener).
| Cases | Controls | Total | |
|---|---|---|---|
| Upper |
|
|
|
| Lower |
|
|
|
| Total |
|
|
|
Figure 1Odds ratios and 95% confidence limits for all PCB blood-level congeners as associated with NHL and reported in six case-control studies.
Figure 2Meta-analyzed congeners indicating Mantel-Haenszel-adjusted odds ratios and 95% confidence limits for all PCB blood-level congeners with two or more strata including the ORMH for all congeners combined. Congeners with single study analyses are also included (congeners 99, 156, 183, and 187). Statistically significant confidence intervals are indicated (∗). Meta-analyzed upper percentile cutoff PCB blood-level values are also included for each congener (ng/g lipid).
List of contributing strata and OR metrics satisfying the meta-analysis criteria. Results of the Chi-square test for homogeneity (P values and degrees of freedom, DOF) are shown for each meta-analyzed congener. Note that congener 118 is statistically heterogeneous (P < 0.025). However, removal of the weighted outlier [46] indicated homogeneity in the remaining strata. A combined test of all congeners indicated overall homogeneity (P > 0.10 and 37 DOF).
| Study (strata) | Percentile type | PCB congener | OR | LCL | UCL | Homogeneity test (Chi-Square DOF) |
|---|---|---|---|---|---|---|
| Spinelli et al., 2007 [ | Tertile | 28 | 0.95 | 0.67 | 1.34 |
|
| Cocco et al., 2008 [ | Quartile | 28 | 1.60 | 0.80 | 3.20 | |
|
| ||||||
| Spinelli et al., 2007 [ | Quartile | 99 | 1.27 | 0.86 | 1.87 |
|
| De Roos et al., 2005 [ | Quartile | 99 | 0.77 | 0.28 | 2.10 | |
|
| ||||||
| Engel et al., 2007-J [ | Quartile | 118 | 1.70 | 0.90 | 3.50 |
|
| Engel et al., 2007-C [ | Quartile | 118 | 5.40 | 1.70 | 17.10 | |
| Spinelli et al., 2007 [ | Quartile | 118 | 1.77 | 1.15 | 2.72 | |
| De Roos et al., 2005 [ | Quartile | 118 | 0.73 | 0.29 | 1.84 | |
| Cocco et al., 2008 [ | Quartile | 118 | 0.40 | 0.20 | 0.80 | |
| Laden et al., 2010 [ | Quartile | 118 | 0.81 | 0.42 | 1.56 | |
| Bertrand et al., 2010 [ | Quintile | 118 | 1.40 | 0.76 | 2.50 | |
|
| ||||||
| Engel et al., 2007-J [ | Quartile | 138 | 1.70 | 0.80 | 3.20 |
|
| Engel et al., 2007-C [ | Quartile | 138 | 4.40 | 1.50 | 12.60 | |
| Spinelli et al., 2007 [ | Quartile | 138 | 1.46 | 0.98 | 2.18 | |
| Cocco et al., 2008 [ | Quartile | 138 | 1.10 | 0.60 | 2.00 | |
| Laden et al., 2010 [ | Quartile | 138 | 0.95 | 0.49 | 1.83 | |
| Bertrand et al., 2010 [ | Quintile | 138 | 1.80 | 0.98 | 3.20 | |
|
| ||||||
| Engel et al., 2007-J [ | Quartile | 153 | 2.00 | 1.00 | 3.90 |
|
| Engel et al., 2007-C [ | Quartile | 153 | 2.20 | 0.90 | 5.20 | |
| Spinelli et al., 2007 [ | Quartile | 153 | 1.79 | 1.17 | 2.72 | |
| De Roos et al., 2005 [ | Quartile | 153 | 1.59 | 0.63 | 4.00 | |
| Cocco et al., 2008 [ | Quartile | 153 | 1.00 | 0.70 | 2.50 | |
| Laden et al., 2010 [ | Quartile | 153 | 0.82 | 0.43 | 1.56 | |
| Bertrand et al., 2010 [ | Quintile | 153 | 2.10 | 1.10 | 3.80 | |
|
| ||||||
| Spinelli et al., 2007 [ | Quartile | 156 | 1.77 | 1.14 | 2.74 |
|
| De Roos et al., 2005 [ | Quartile | 156 | 2.70 | 0.97 | 7.50 | |
|
| ||||||
| Spinelli et al., 2007 [ | Quartile | 170 | 1.80 | 1.16 | 2.79 |
|
| De Roos et al., 2005 [ | Quartile | 170 | 1.73 | 0.73 | 4.14 | |
| Cocco et al., 2008 [ | Quartile | 170 | 1.00 | 0.50 | 1.80 | |
|
| ||||||
| Spinelli et al., 2007 [ | Quartile | 180 | 1.91 | 1.19 | 3.07 |
|
| De Roos et al., 2005 [ | Quartile | 180 | 3.50 | 1.34 | 9.15 | |
| Laden et al., 2010 [ | Quartile | 180 | 1.03 | 0.52 | 2.02 | |
| Cocco et al., 2008 [ | Quartile | 180 | 1.50 | 0.70 | 3.20 | |
| Bertrand et al., 2010 [ | Quintile | 180 | 2.40 | 1.30 | 4.50 | |
|
| ||||||
| Spinelli et al., 2007 [ | Tertile | 183 | 1.22 | 0.87 | 1.71 |
|
| De Roos et al., 2005 [ | Quartile | 183 | 1.02 | 0.36 | 2.93 | |
|
| ||||||
| Spinelli et al., 2007 [ | Quartile | 187 | 1.92 | 1.23 | 2.98 |
|
| De Roos et al., 2005 [ | Quartile | 187 | 1.22 | 0.49 | 3.08 | |
Figure 3Ecological correlations between PCB accumulation and the national incidence of NHL compared over calendar years and relative year based on the assumptions of (a) sales-only exposure (sales model); (b) environmental exposure (static model); (c) physiologic exposure (dynamic model).
Summary of the dose-response correlations between synchronized polychlorinated biphenyl (PCB) bioaccumulation and the incidence of cancer. Accumulation is represented as based on sales alone (sales growth), environmental exposure (static growth), and physiologic exposure (dynamic growth).
| Cancer type | Statistical correlation with PCB accumulation ( | ||
|---|---|---|---|
| Sales only (sales) | Environment (static) | Physiologic (dynamic) | |
| Non-Hodgkin lymphoma | 0.9813 | 0.9427 | 0.9850 |
| All cancers | 0.9754 | 0.8874 | 0.3523 |
| Hodgkin lymphoma | 0.2077 | 0.0062 | 0.0273 |
| Pancreatic | 0.0411 | 0.0979 | 0.0001 |
| Liver and bile duct | 0.8834 | 0.5960 | 0.9715 |
| Kidney and renal | 0.9399 | 0.7022 | 0.9534 |
| Bone and joint | 0.1190 | 0.1156 | 0.1486 |
| Brain and nervous system | 0.7966 | 0.5746 | 0.0800 |
| Digestive system | 0.0089 | 0.4168 | 0.8548 |
| Leukemia | 0.0913 | 0.0248 | 0.0081 |
| Lung | 0.8826 | 0.5600 | 0.0236 |
| Skin | 0.9166 | 0.7254 | 0.9378 |
| Oral | 0.4224 | 0.5994 | 0.8910 |
| Soft tissue and heart | 0.3322 | 0.5377 | 0.9118 |
| Urinary bladder | 0.7153 | 0.7050 | 0.3750 |
| Breast (female) | 0.9076 | 0.8639 | 0.3546 |
| Genital system (female) | 0.6892 | 0.7718 | 0.6825 |
| Prostate (male) | 0.8369 | 0.7290 | 0.3808 |